New hope for kids battling rare, painful disease
NCT ID NCT05001269
Summary
This study tested a drug called nedosiran in young children with primary hyperoxaluria, a rare genetic disease that causes the body to produce too much of a substance called oxalate. The oxalate can damage the kidneys and other organs. The main goal was to see if monthly doses of nedosiran could safely lower the amount of oxalate in the children's urine over six months and help protect their kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPEROXALURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Site
Rochester, Minnesota, 55905, United States
-
Clinical Research Site
Hamilton, Ontario, L8S 4K1, Canada
-
Clinical Research Site
Heidelberg, 69120, Germany
-
Clinical Research Site
Fukuoka, 830-0011, Japan
-
Clinical Research Site
Nagoya, 467-8602, Japan
-
Clinical Research Site
Beirut, 1100, Lebanon
-
Clinical Research Site
Bialystok, 15-274, Poland
-
Clinical Research Site
Barcelona, 08035, Spain
-
Clinical Research Site
Yenimahalle, Ankara, 06506, Turkey (Türkiye)
-
Clinical Trial Site
Bonn, 53127, Germany
-
Clinical Trial Site
Roma, 00165, Italy
-
Clinical Trial Site
Dubai, +971, United Arab Emirates
-
Clinical Trial Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.